arrow_back Back to App

Drugs without China-sourced ingredients: new purchase rules and tax breaks.

This act aims to restrict US government health programs from purchasing drugs with ingredients from China, potentially affecting drug availability and prices. It also introduces tax breaks for companies manufacturing drugs and medical devices in the US, encouraging local production and enhancing supply security. Citizens may experience changes in drug availability and origin.
Key points
Starting in 2028, federal health programs will gradually limit the purchase of drugs with active ingredients from China, completely avoiding them by 2030.
A labeling requirement for the country of origin of each active ingredient in drugs is introduced, increasing transparency for consumers.
Companies manufacturing drugs and medical devices in the US can benefit from temporary tax breaks (100% deduction for investment costs) until the end of 2030, supporting domestic production.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_1407
Sponsor: Sen. Cotton, Tom [R-AR]
Process start date: 2025-04-10
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

ABC Safe Drug Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1407.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-04-10.

What are the main provisions?

Key points include:

  • Starting in 2028, federal health programs will gradually limit the purchase of drugs with active ingredients from China, completely avoiding them by 2030.
  • A labeling requirement for the country of origin of each active ingredient in drugs is introduced, increasing transparency for consumers.
  • Companies manufacturing drugs and medical devices in the US can benefit from temporary tax breaks (100% deduction for investment costs) until the end of 2030, supporting domestic production.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cotton, Tom [R-AR].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Taxes Economy